{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:19:55Z","timestamp":1792552795868,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejso.2026.111805","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T15:42:24Z","timestamp":1776354144000},"page":"111805","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Surgical outcomes after neoadjuvant chemoimmunotherapy for resectable NSCLC: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6267-0099","authenticated-orcid":false,"given":"Pietro","family":"Bertoglio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5579-0837","authenticated-orcid":false,"given":"Filippo Tommaso","family":"Gallina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7837-4457","authenticated-orcid":false,"given":"Eleonora","family":"Balzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ambrosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Di Federico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Faccioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4555-1725","authenticated-orcid":false,"given":"Giorgio","family":"Facheris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1163-3765","authenticated-orcid":false,"given":"Alessandra","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Filipello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4592-8868","authenticated-orcid":false,"given":"Raffaele","family":"Giusti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Mammana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Marinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3571-7006","authenticated-orcid":false,"given":"Antonio","family":"Nuccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9024-1064","authenticated-orcid":false,"given":"Alessandra","family":"Pittaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Sepulcri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Viscardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4125-4379","authenticated-orcid":false,"given":"Francesco","family":"Guerrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ejso.2026.111805_bib1","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41571-021-00501-4","article-title":"Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer","volume":"18","author":"Chaft","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"21","key":"10.1016\/j.ejso.2026.111805_bib2","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","article-title":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group","volume":"26","author":"Pignon","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2026.111805_bib3","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1001\/jamaoncol.2024.0057","article-title":"Neoadjuvant chemoimmunotherapy for NSCLC: a systematic review and meta-analysis","volume":"10","author":"Sorin","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejso.2026.111805_bib4","article-title":"Safety and efficacy of salvage surgery after treatment with immune-checkpoint adjuvant inhibitors for advanced non-small cell lung cancer: a multicentric study","author":"Schiavon","year":"2024","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ejso.2026.111805_bib5","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.ejso.2026.111805_bib6","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejso.2026.111805_bib7","series-title":"Cochrane handbook for systematic reviews of interventions (version 6.5","author":"A Higgins","year":"2024"},{"issue":"10","key":"10.1016\/j.ejso.2026.111805_bib8","first-page":"ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"10.1016\/j.ejso.2026.111805_bib9","first-page":"e14","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"379","author":"Forde","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ejso.2026.111805_bib10","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1038\/s41591-022-01962-5","article-title":"Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial","volume":"28","author":"Chaft","year":"2022","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.ejso.2026.111805_bib11","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jtho.2020.01.017","article-title":"Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC","volume":"15","author":"Gao","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2026.111805_bib12","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41591-020-01224-2","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial","volume":"27","author":"Cascone","year":"2021","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.ejso.2026.111805_bib13","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41591-022-02189-0","article-title":"Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial","volume":"29","author":"Cascone","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.ejso.2026.111805_bib14","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.lungcan.2021.01.018","article-title":"Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: first clinical experience","volume":"153","author":"Eichhorn","year":"2021","journal-title":"Lung Cancer"},{"issue":"10","key":"10.1016\/j.ejso.2026.111805_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005636","article-title":"Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO)","volume":"10","author":"Wislez","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"21","key":"10.1016\/j.ejso.2026.111805_bib16","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ejso.2026.111805_bib17","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1158\/2159-8290.CD-23-0436","article-title":"Neoadjuvant durvalumab alone or combined with novel immuno-oncology agents in resectable lung cancer: the phase II NeoCOAST platform trial","volume":"13","author":"Cascone","year":"2023","journal-title":"Cancer Discov"},{"issue":"10","key":"10.1016\/j.ejso.2026.111805_bib18","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1001\/jamaoncol.2023.2751","article-title":"Neoadjuvant camrelizumab plus platinum-based chemotherapy vs chemotherapy alone for Chinese patients with resectable stage IIIA or IIIB (T3N2) non-small cell lung cancer: the TD-FOREKNOW randomized clinical trial","volume":"9","author":"Lei","year":"2023","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2026.111805_bib19","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.athoracsur.2017.09.030","article-title":"Surgical outcomes after neoadjuvant chemotherapy and ipilimumab for non-small cell lung cancer","volume":"105","author":"Yang","year":"2018","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"10.1016\/j.ejso.2026.111805_bib20","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.athoracsur.2022.01.039","article-title":"Neoadjuvant sintilimab and chemotherapy for resectable stage IIIA non-small cell lung cancer","volume":"114","author":"Zhang","year":"2022","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.ejso.2026.111805_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102422","article-title":"Efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy in potentially resectable stage IIIA\/IIIB non-small cell lung cancer: Neo-Pre-IC, a single-arm phase 2 trial","volume":"68","author":"Sun","year":"2024","journal-title":"eClinicalMedicine"},{"issue":"11","key":"10.1016\/j.ejso.2026.111805_bib22","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S1470-2045(20)30453-8","article-title":"Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Provencio","year":"2020","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2026.111805_bib23","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa2215530","article-title":"Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer","volume":"389","author":"Provencio","year":"2023","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.ejso.2026.111805_bib24","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1200\/JCO.21.00276","article-title":"SAKK 16\/14: durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small-cell lung Cancer-A multicenter single-arm phase II trial","volume":"39","author":"Rothschild","year":"2021","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.ejso.2026.111805_bib25","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non-small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ejso.2026.111805_bib26","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non-small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ejso.2026.111805_bib27","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jama.2023.24735","article-title":"Perioperative toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: the neotorch randomized clinical trial","volume":"331","author":"Lu","year":"2024","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ejso.2026.111805_bib28","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jtcvs.2021.02.099","article-title":"Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non-small cell lung cancer","volume":"163","author":"Tong","year":"2022","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"1","key":"10.1016\/j.ejso.2026.111805_bib29","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41392-023-01355-1","article-title":"Two vs three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small-cell lung cancer: neoSCORE trial","volume":"8","author":"Shao","year":"2023","journal-title":"Signal Transduct Targeted Ther"},{"issue":"6","key":"10.1016\/j.ejso.2026.111805_bib30","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/S1470-2045(20)30140-6","article-title":"Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Shu","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2026.111805_bib31","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1996000","article-title":"Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer","volume":"10","author":"Zhao","year":"2021","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ejso.2026.111805_bib32","series-title":"Conference Abstract presented at: ESMO Virtual Congress 2020","article-title":"Atezolizumab for resectable non-small cell lung cancer","author":"Princeps study","year":"2020"},{"issue":"6","key":"10.1016\/j.ejso.2026.111805_bib33","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.jtho.2023.02.019","article-title":"Efficacy, safety, and biomarker analysis of neoadjuvant camrelizumab and apatinib in patients with resectable NSCLC: a phase 2 clinical trial","volume":"18","author":"Zhao","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"19","key":"10.1016\/j.ejso.2026.111805_bib34","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","article-title":"Perioperative nivolumab in resectable lung cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ejso.2026.111805_bib35","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S2213-2600(24)00269-8","article-title":"Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial","volume":"13","author":"Yue","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.ejso.2026.111805_bib36","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/j.athoracsur.2017.03.038","article-title":"Initial experience with lung cancer resection after treatment with T-Cell checkpoint inhibitors","volume":"104","author":"Chaft","year":"2017","journal-title":"Ann Thorac Surg"},{"issue":"6","key":"10.1016\/j.ejso.2026.111805_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2025.109592","article-title":"The outcomes of salvage surgery for non-small cell lung cancer after immune checkpoint inhibitor or targeted therapy treatment. A multi-center international real-life study","volume":"51","author":"Guerrera","year":"2025","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2026.111805_bib38","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jtcvs.2018.11.124","article-title":"Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer","volume":"158","author":"Bott","year":"2019","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"5","key":"10.1016\/j.ejso.2026.111805_bib39","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.jtcvs.2022.01.019","article-title":"Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer","volume":"164","author":"Sepesi","year":"2022","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"10","key":"10.1016\/j.ejso.2026.111805_bib40","article-title":"Important surgical and clinical end points in neoadjuvant immunotherapy trials in resectable NSCLC","volume":"2","author":"Lee","year":"2021","journal-title":"JTO Clin Res Rep"},{"issue":"2","key":"10.1016\/j.ejso.2026.111805_bib41","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jtcvs.2022.12.006","article-title":"Safety and feasibility of minimally invasive lobectomy after neoadjuvant immunotherapy for non-small cell lung cancer","volume":"166","author":"Mathey-Andrews","year":"2023","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"5","key":"10.1016\/j.ejso.2026.111805_bib42","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.cllc.2024.03.008","article-title":"Video-assisted thoracoscopic surgery versus thoracotomy following neoadjuvant immunochemotherapy in resectable stage III non-small cell lung cancer among Chinese populations: a multi-center retrospective cohort study","volume":"25","author":"Pan","year":"2024","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ejso.2026.111805_bib43","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241265214","article-title":"Analysis of surgical complexity and short-term prognostic indicators in NSCLC patients: neoadjuvant targeted therapy versus neoadjuvant chemoimmunotherapy","volume":"16","author":"Wang","year":"2024","journal-title":"Ther Adv Med Oncol"},{"issue":"15","key":"10.1016\/j.ejso.2026.111805_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15153908","article-title":"A systematic review of short-term outcomes of minimally invasive thoracoscopic surgery for lung cancer after neoadjuvant systemic therapy","volume":"15","author":"Sedighim","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.ejso.2026.111805_bib45","doi-asserted-by":"crossref","first-page":"e600","DOI":"10.1097\/SLA.0000000000005233","article-title":"Radical minimally invasive surgery after immuno-chemotherapy in initially-unresectable stage IIIB non-small cell lung cancer","volume":"275","author":"Deng","year":"2022","journal-title":"Ann Surg"},{"issue":"3","key":"10.1016\/j.ejso.2026.111805_bib46","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jtcvs.2024.08.012","article-title":"Determinants of successful minimally invasive surgery for resectable non-small cell lung cancer after neoadjuvant therapy","volume":"169","author":"Chu","year":"2025","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"3","key":"10.1016\/j.ejso.2026.111805_bib51","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jtcvs.2022.10.007","volume":"165","author":"Rusch","year":"2023","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"7","key":"10.1016\/j.ejso.2026.111805_bib52","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jtho.2022.04.012","article-title":"Three-year Follow-Up of neoadjuvant programmed cell death Protein-1 inhibitor (Sintilimab) in NSCLC","volume":"17","author":"Zhang","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2026.111805_bib53","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/ejcts\/ezab007","article-title":"Outcomes of surgical resection after neoadjuvant chemoimmunotherapy in locally advanced stage IIIA non-small-cell lung cancer","volume":"60","author":"Romero Roman","year":"2021","journal-title":"Eur J Cardio Thorac Surg"},{"key":"10.1016\/j.ejso.2026.111805_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108760","article-title":"Attrition with adjuvant, neoadjuvant, and perioperative immunotherapy-based treatment protocols in patients with resectable non-small-cell lung cancer. A meta-analysis of prospective trials","volume":"209","author":"Guerrera","year":"2025","journal-title":"Lung Cancer"},{"issue":"13","key":"10.1016\/j.ejso.2026.111805_bib47","doi-asserted-by":"crossref","first-page":"8508","DOI":"10.1245\/s10434-024-16284-8","article-title":"Association of neoadjuvant immunotherapy with postoperative major morbidity after oncologic surgery","volume":"31","author":"Habib","year":"2024","journal-title":"Ann Surg Oncol"},{"issue":"14","key":"10.1016\/j.ejso.2026.111805_bib48","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/1759-7714.15297","article-title":"Surgery challenges and postoperative complications of lung cancer after neoadjuvant immunotherapy","volume":"15","author":"Bai","year":"2024","journal-title":"Thorac Cancer"},{"issue":"12","key":"10.1016\/j.ejso.2026.111805_bib49","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2026.111805_bib50","article-title":"Outcomes after neoadjuvant therapy with or without immunotherapy followed by pneumonectomy in non-small cell lung cancer patients","author":"Li","year":"2024","journal-title":"Ann Thorac Surg"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326004245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326004245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T22:58:35Z","timestamp":1779577115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798326004245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0748798326004245"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2026.111805","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Surgical outcomes after neoadjuvant chemoimmunotherapy for resectable NSCLC: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2026.111805","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111805"}}